Molecular Screening Test Detects Colorectal Cancer
|
By LabMedica International staff writers Posted on 12 Oct 2010 |
|
Image: Colored scanning electron micrograph (SEM) of cancer cells from the human colon (photo courtesy Susumu Nishinaga / SPL).
A ribonucleic acid (RNA) screening assay detected the majority of early-stage colorectal cancers with good specificity and sensitivity.
Blood plasma samples collected from patients with early, resectable (Stage II) colorectal cancer and sex- and age-matched healthy volunteers were screened using a state of the art method for micro RNA (miRNA).
The method was based on the miRCURY locked nucleic acid (LNA) Universal reverse transcriptase miRNA polymerase chain reaction analysis. Early-stage colorectal cancer could be distinguished from healthy subjects with good sensitivity and specificity from a single plasma sample of less than 1 mL of blood.
The miRCURY LIN assays are manufactured by Exiqon A/S, (Vedbaek, Denmark). Exiqon's miRNA arrays feature normalized enhanced LNA capture probes, designed for excellent specificity and sensitivity even for AT-rich miRNAs. In addition, they offer great reproducibility with 99% correlation between arrays and a dynamic range greater than four orders of magnitude.
Colorectal cancer is the second leading cause of cancer-related deaths in the western world. If diagnosed early, the disease can usually be cured with surgery; however, the prognosis for late-stage cancer is bleak. Although several early-detection screening methods are available, current estimates suggest that less than half of Americans over the age of 50 receive adequate colorectal cancer screening. The findings were presented at the Fourth American Association for Cancer Research's International Conference on Molecular Diagnostics in Cancer Therapeutic Development that was held during September 23 – 27, 2010, in Denver (CO, USA).
Søren Jensby Nielsen, Ph.D., scientific manager, Exiqon A/S, said, "Our test has the potential to be safe, cheap, robust, accurate and of little or no inconvenience to the individual, and could, therefore, easily be integrated into national screening programs as part of an annual checkup."
Nielsen and colleagues are starting a large, prospective clinical trial in symptomatic individuals undergoing colonoscopy to validate prospectively their screening test. The scientist envision that this type of miRNA profile, once developed and marketed as a screening kit, can be used to screen entire populations in order to facilitate a focused selection of individuals who should undergo colonoscopy.
Related Links:
Exiqon A/S
.jpg)
Blood plasma samples collected from patients with early, resectable (Stage II) colorectal cancer and sex- and age-matched healthy volunteers were screened using a state of the art method for micro RNA (miRNA).
The method was based on the miRCURY locked nucleic acid (LNA) Universal reverse transcriptase miRNA polymerase chain reaction analysis. Early-stage colorectal cancer could be distinguished from healthy subjects with good sensitivity and specificity from a single plasma sample of less than 1 mL of blood.
The miRCURY LIN assays are manufactured by Exiqon A/S, (Vedbaek, Denmark). Exiqon's miRNA arrays feature normalized enhanced LNA capture probes, designed for excellent specificity and sensitivity even for AT-rich miRNAs. In addition, they offer great reproducibility with 99% correlation between arrays and a dynamic range greater than four orders of magnitude.
Colorectal cancer is the second leading cause of cancer-related deaths in the western world. If diagnosed early, the disease can usually be cured with surgery; however, the prognosis for late-stage cancer is bleak. Although several early-detection screening methods are available, current estimates suggest that less than half of Americans over the age of 50 receive adequate colorectal cancer screening. The findings were presented at the Fourth American Association for Cancer Research's International Conference on Molecular Diagnostics in Cancer Therapeutic Development that was held during September 23 – 27, 2010, in Denver (CO, USA).
Søren Jensby Nielsen, Ph.D., scientific manager, Exiqon A/S, said, "Our test has the potential to be safe, cheap, robust, accurate and of little or no inconvenience to the individual, and could, therefore, easily be integrated into national screening programs as part of an annual checkup."
Nielsen and colleagues are starting a large, prospective clinical trial in symptomatic individuals undergoing colonoscopy to validate prospectively their screening test. The scientist envision that this type of miRNA profile, once developed and marketed as a screening kit, can be used to screen entire populations in order to facilitate a focused selection of individuals who should undergo colonoscopy.
Related Links:
Exiqon A/S
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Pipette Calibration System
Artel PCS®
Latest Molecular Diagnostics News
- New PCR Assays Expand Cyclospora Testing for Outbreak Surveillance
- Single Liquid Biopsy Predicts Early Immunotherapy Benefit in Advanced Lung Cancer
- Machine Learning Tool Improves Prediction of Liver Cancer Recurrence
- AI-Powered Liquid Biopsy Detects Liver Cancer Across Diverse Populations
- Circular RNAs Enable Noninvasive Cancer Detection and Risk Assessment
- Polygenic Risk Score Test Estimates Inherited Coronary Artery Disease Risk
- AI Tool Improves Long-Read Detection of Cancer Mutations
- FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
- Blood Gene Expression Fluctuates More Than Expected Over Time
- Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer
- Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
- Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
- Portable Rapid Test Aims to Detect Ebola at Point of Care
- New Test Delivers Four Prenatal Genetic Screens from One Blood Sample
- Point-of-Care Molecular Technology Promises Transformative Shift in Oncology
- Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
Channels
Clinical Chemistry
view channel
Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more
Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
Multiple sclerosis (MS) remains difficult to monitor because neurological decline can continue even after relapses stop. This progression independent of relapse activity is often subtle and may escape... Read more
Hematology
view channel
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Immunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read more
Pathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Technology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more
